A clinical trial update for larazotide, also known as AT1001, was recorded on May 22, 2026. The study, registered as NCT05747534 and titled "AT1001 for the Treatment of Long COVID," is a Phase 2 trial. Its current status is listed as active, not recruiting. This means enrollment for the trial has closed, but the study is continuing with participants already enrolled. Larazotide remains classified as an unapproved research compound, and this update does not indicate any results or outcomes from the trial. The status change reflects only the trial's operational stage, not any findings about safety or effectiveness. No efficacy or safety data have been reported as part of this update. Researchers and interested parties can track further developments through the trial's official registration page. For more background on larazotide and its research context, readers can consult the compound overview.
Larazotide (AT1001) Long COVID Trial Now Active, Not Recruiting
See the full larazotide overview
Source: https://clinicaltrials.gov/study/NCT05747534